News | May 29, 2026
AbbVie wins FDA nod for DECNUPAZ in rare blood cancer
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
The decision marks a key step in the centralized EU review process
With standout ADC and t-cell engager response data across hard-to-treat cancers
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Subscribe To Our Newsletter & Stay Updated
